NVCR NovoCure Limited
$16.31▼ -4.23%
Unknown
Other
Last sync: 8m ago
Syncing
Key Metrics & Fundamentals
Market Cap
$1.89B
P/E Ratio
–
Div Yield
–%
52W Range
9.82 - 21.45
% vs 50 MA
-0.26%
% vs 200 MA
20.78%
RSI-14
50.2
MACD Histogram
+0.1000
Beta (1Y vs SPY)
1.81
Gross Rev
$674.41M
Gross Profit
$508.84M
EBITDA
-$166.22M
COGS
$165.58M
Operating Exp
$675.05M
Operating Income
–
EBIT
–
Pretax Income
–
Net Income
–
Price & Volume History
Volume (M)
Financial Overview - Income Statement
Quarterly
Jun 2026 (Quarterly)
Social Sentiment
Avg +0.68 · 5 posts
This is a Wow. Pancreatic cancer used to be a brutal death sentence
r/stocks · Feb 12, 2026
The post expresses excitement about the FDA approval and suggests the company's market cap is undervalued, indicating a bullish sentiment.
positive
+0.60
NewsTradeNovoCure's Tumor-Treating Electric Fields Shows Promise In Pancreatic Cancer Patients
r/wallstreetbets · Dec 2, 2024
Significant positive trial data and stock price movement discussed.
very_positive
+1.00
NewsTradeDDThese are the stocks on my watchlist (12/2)
r/StockMarket · Dec 2, 2024
Mentioned as having a potentially higher fair value based on an analysis.
positive
+0.40
NewsDiscussionTradeWill $NVCR have a rebound?
r/wallstreetbets · Nov 25, 2024
The post shows cautious optimism due to recent FDA approval, trial successes, and new leadership, though previous drops are acknowledged.
positive
+0.60
NewsDiscussionTrade$NVCR Bullish PANOVA-3 Trial
r/wallstreetbets · Sep 4, 2024
The post is highly optimistic about NVCR's PANOVA-3 trial results and their potential impact.
very_positive
+0.80
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not Financial Advice.
All data, scores, charts, and analysis on this site are provided for informational and educational purposes only
and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
Always consult a qualified financial advisor before making any investment decisions.
See our Legal Notice for full details.